Antitumor diarylsulfonylureas: novel agents with unfulfilled promise.
Diarylsulfonylureas represent a class of antitumor agent with significant therapeutic efficacy against rodent and human models of cancer. Despite the exciting preclinical activity of sulofenur, the prototypic agent, clinical activity was poor. Here we review the activity of sulofenur and a second generation diarylsulfonylurea, LY295501 N-[5-(2, 3-dihydrobenzofuryl) sulfonyl]-N'-(3,4-dichlorophenyl)urea, against colon tumor xenografts, and some of the cellular pharmacology of this class of antitumor agents.
Houghton
P J
PJ
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
Houghton
J A
JA
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001572:Benzofurans / Q000737:chemistry / Q000627:therapeutic use*; D002648:Child; D017321:Clinical Trials, Phase I as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D018432:Drug Resistance, Multiple; D006801:Humans; D010671:Phenylurea Compounds / Q000737:chemistry / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000737:chemistry / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
D000970:Antineoplastic Agents; D001572:Benzofurans; D010671:Phenylurea Compounds; D013453:Sulfonylurea Compounds; C094382:N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea; C058179:sulofenur